Clinical Research Directory

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

The purpose of this research is to compare weight loss among 3 groups: 1. people who stay on a GLP-1 drug at full strength (Group 1) 2. people who have their dose tapered to every other week, meaning slowly decreasing the dose and frequency of the full prescription you are currently taking (Group 2) 3. people who go off their GLP-1 and instead take an alternative weight loss drug or combination of drugs called phentermine \& topiramate. These are not GLP-1 medications. (Group 3) The investigators want to see if the second and third options are effective at weight loss maintenance. This study will include a total of 60 participants. Participants will be randomly assigned to one of the three study groups. The goals of this current study are to: 1. determine the acceptability of these proposed treatment strategies, 2. collect data about how people's weight changes early on and throughout the study and how well people tolerate the medications. 3. determine whether it is feasible to recruit for a larger, follow-up study. There are 3 on-site visits: at the start, and then 6 and 12 months. The study team will do monthly phone calls in between those visits. At the on-site visits the study team will do various physical measures and collect blood for lab testing and provide participants with counseling to help with weight loss. The study team will instruct participants in a home-based resistance exercise regimen to help maintain muscle mass. This will include exercises such as: sit-to-stand, mini-squats, calf raises, leg extension, wall press-up, and bicep curls two to three times a week. If these exercises are deemed too easy, participants may choose to do regular pushups, planks, lunges and/or add a resistance band.

Effects of a Multispecies Probiotic on Metabolic, Liver, and Gut Health

The goal of this clinical trial is to learn if multistrain probiotic works to improve severe metabolic markers and gastrointestinal symptoms in obese MASLD patients. The main questions it aims to answer are Does this multistrain probiotic improve the composition of gut microbiota? Does it improve gastrointestinal symptoms and metablic profiles? Does it help in improving the grade of liver steatosis, and lose weight? Researchers will compare a multistrain probiotic group to a control group. Participants will: The probiotic group will take multistrain probiotics daily for 6 months in addition to a dietary plan and physical activity recommendations. The control group will only follow a dietary plan and physical activity recommendations Visit the clinic every 3 months for checkups and be called every month for regular follow-ups

The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes

The aim of the study is to evaluate the effect of a 12-week liraglutide treatment as an addition to dietary intervention in comparison to dietary intervention alone on body weight, body composition, ectopic lipid accumulation and insulin sensitivity in subjects with overweight or obesity.

Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea

When used, continuous positive airway pressure (CPAP) is an effective treatment for obstructive sleep apnea (OSA), a condition that is mainly caused by overweight and obesity. However, CPAP is plagued by poor adherence and high rates of discontinued use leaving most patients undertreated and at risk of serious health complications. This study aims to test whether new effective weight loss pharmacotherapy is superior to CPAP for alleviating OSA and improving health outcomes.

ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation

This randomized controlled trial aims to evaluate the efficacy and safety of Endoscopic Radial Compression Gastroplasty (ERCG) in mitigating weight regain following discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approximately 60 adults with prior GLP-1 RA use and confirmed weight rebound after treatment cessation will be randomized 1:1 to either ERCG combined with Intensive Lifestyle Intervention (ILI), or ILI alone. The primary outcome is the between-group difference in percent Total Body Weight Loss (%TBWL) from randomization to week 12; secondary outcomes include %TBWL at 24 and 52 weeks; changes in Body Mass Index (BMI), body composition, metabolic parameters (e.g., glycemic control, lipid profile), and quality of life; adherence to ILI; and adverse events, all assessed over 12, 24 and 52-week follow-up period. This study will generate preliminary evidence on the effectiveness and safety of ERCG as an intervention for weight regain after GLP-1 RA withdrawal, and the results will inform the design of future confirmatory trials, including sample size and endpoint selection.

Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs

Drug overdose is a national crisis. The primary cause of death associated with opioids is opioid-induced respiratory depression. Naloxone (Narcan) which is the first line of defense for opioid overdose can reverse OIRD (Opioid-Induced Respiratory Depression), but in post-operative patients it will abolish pain control. There are no medications that can prevent OIRD. Pre-clinical studies provided evidence that intranasal (administered via a nasal spray) oxytocin may prevent and treat OIRD without interfering with pain control.

Sustaining Health After an Intensive Weight-loss Pro-gramme

Since 2021 Copenhagen University Hospital - Hvidovre, Denmark, has offered a 2-year, highly specialised, intensive clinical weight loss programme to patients living with severe and complex obesity, who due to somatic and/or psychiatric comorbidity are not eligible for bariatric surgery. This understudied group often lacks treatment options despite significant functional impairment and high healthcare costs. The programme is based on an intensive dietary and behavioural support provided by trained dieti-cians. It begins with an 8-week period of full TDR of 800 kcal/day. During this initial phase the patients have bimonthly consultations with the dieticians, a schedule which continues throughout the first year. At week 6-8 the patients begin the treatment with GLP-1 receptor agonist (GLP-1-RA). Until medio 2024 patients without diabetes were treated with Liraglutide, thereafter Semaglutide has been used. After week 8 the patients transition back to a normal balanced diet, guided by the dieticians. Shorter periods of TDR can be used as a rescue-strategy in cases of weight-regain during the treat-ment period. In their second year of treatment the frequency of dietician consultations de-creases to once a month. Patients are scheduled to see a physician at the beginning of the treatment, at 4 months, at 12 months and at 21 months. At the end of the programme dieticians and physicians' advice on weight loss maintenance strategies including possibilities for cessation/reducing dose of weight loss medication but there are no clinical follow up visits. Overall research question What is the durability and long-term health effects of a hospital-based IWL-treatment programme, with specific attention to cardiometabolic health, body-composition and health-related quality of life, at least 1 year after cessation of treatment in a clinical cohort of patients living with severe obesity and multimorbidity? Study design This study is a post-intervention observational follow-up (FU) study, evaluating the durability of the IWL-treatment offered to patients at Hvidovre Hospital since 2022. This study is a substudy under the study-compilation SHAPe, consisting of a quality-assurance project evaluating the treatment programme, this post-intervention observational FU-study, a qualitative study exploring psychosocial and socio-economic precarity mediate adherence to the programme and durability of health outcomes and a societal and economic impact study to evaluate the impact on total health care costs and labour market attachment. The FU-visit will consist of a single investigation day at Hvidovre Hospital and will be scheduled at least 12 months after completing the treatment programme. Participants will provide blood and urine samples, undergo anthropometric measurements (weight, height, waist circumference), blood pressure assessment, and body composition analysis. They will also complete the SF-36 questionnaire and a . Additionally, they will be asked for consent to link their data to national registries for a 10-year follow-up on hospital admissions, medication use, and employment status. Biological samples may be stored for future analysis of metabolic biomarkers related to weight regulation. Due to the clinical nature of the study, it is exploratory and descriptive and hence does not include hypothesis testing, but instead an overall research question. Thus, it is designed with a non-hierarchical outcome structure, though with certain patient-centred "key outcomes." These outcomes have been chosen to reflect what is important for patients lives with skeletal muscle mass, health-related quality of life and weight as key outcomes. Additionally, we will explore the following outcomes: fat-mass, waist circumference, use of weight-loss medication, lower body strength, blood-pressure, HbA1c, lipid levels and potential proteomic biomarkes associated with regain vs weight maintenance. We aim to include 200 participants in the FU study.

Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity

This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that reduces the size of the stomach. Adults starting GLP-1 medications as part of their usual care will be followed for 24 months. Their results will be compared with existing medical records of adults who underwent sleeve gastrectomy at the same center. Treatment decisions will be made by patients and their treating clinicians as part of routine care, rather than assigned by the study. The main outcome is the percentage of starting body weight lost at 24 months. The study will also assess weight changes at earlier visits, medication side effects, treatment continuation and reasons for stopping treatment, and changes in weight-related health conditions. The groups will be matched using baseline characteristics to make the comparison more balanced.

Gut Microbiota-Based Clinical Study of Akkermansia Supplementation for Overweight and Obesity

Overweight and obesity are common metabolic disorders associated with increased risks of diabetes, cardiovascular disease, and other health problems. The gut microbiota plays an important role in regulating metabolism, inflammation, and intestinal health. Akkermansia, a beneficial gut bacterium, has been associated with metabolic health and may have potential benefits for weight management. This study aims to investigate the relationship between gut microbiota characteristics and overweight or obesity and to evaluate the efficacy and safety of Akkermansia supplementation in individuals with overweight or obesity. The study consists of two stages. The first stage is an observational study comparing gut microbiota characteristics between healthy individuals and individuals with overweight or obesity. The second stage is a randomized, double-blind, placebo-controlled clinical trial in which eligible participants with overweight or obesity will receive either Akkermansia supplementation or placebo once daily for 12 weeks, followed by follow-up through Week 24. The study will evaluate changes in body weight, metabolic health, gut microbiota characteristics, related metabolites, and safety outcomes. The findings may provide clinical evidence regarding the potential use of Akkermansia supplementation for the management of overweight and obesity.

Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care

This study is testing an 8-week behavioral weight loss and wellness program adapted to the needs of Black/African American breast cancer survivors. The study will also examine psychological and physical factors that may be associated with weight loss outcomes.

Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

This is a multicenter, open-label, superiority randomized controlled trial enrolling adult patients aged 18 to 75 years. All participants have abdominal obesity (BMI ≥ 28 kg/m² with specific waist circumference standards) and non-valvular atrial fibrillation, and have successfully regained normal heart rhythm after their first catheter ablation. The study aims to compare the efficacy and safety of weekly mazdutide injection with conventional routine care in preventing heart rhythm recurrence within 12 months after ablation (excluding a 3-month early recovery blanking period). A total of 24 months will be spent recruiting participants, followed by a 12-month follow-up period. Participants are randomly divided into two groups. The intervention group receives escalating-dose mazdutide subcutaneous injections starting within 48 hours after ablation alongside standard health guidance on diet, exercise and lifestyle. The control group only receives the same routine health guidance without mazdutide treatment. The primary efficacy endpoint is recurrence of atrial arrhythmias (including AF, atrial flutter, and atrial tachycardia) recorded on a standard 12-lead surface ECG for ≥10 seconds, or on a 24-hour Holter monitor (including single-lead ECG patches) for \>30 seconds, at 12 months after a single ablation procedure (after a 3-month blanking period), without the use of any Class I/III antiarrhythmic drugs (AADs).

Impact of Significant Surgical Reduction of Adipose Tissue on Plasma Levels and Genetic Expression of Adipokines Associated With Ischemic Heart Disease in Type I Obesity.

Adipose tissue is with endocrine properties and secretes many cytokines. Some of these cytokines are concerned with ischemic heart disease. I hypothesized that significant surgical reduction in adipose tissue mass leads to decrease in its cell population which may pose significantly reduced production of adipokines ( Leptin and Angiotensin) associated with ischemic heart disease in obese people. Study objectives are analysis of Leptin, Angiotensin-II, mRNA expression analysis of leptin, leptin receptor and Angiotensin-II. investigation of genetic variations in the Leptin, Leptin receptors, Angiotensin-I and Angiotensin-II receptors, confirm SNPs of selected sample. Ddetermination of the association of genetic variation in Leptin receptor, angiotensin-I and Angiotensin-II receptors with Leptin and Angiotensin-II levels and determination of effect of genetic variation on the transcriptional regulation. Case control study having 212 patients (106 patients in each group) with type I Obese adults, both males and pre-menopausal females belonging to ASA 1 and 2 requiring stagged liposuction will be included. Exclusion of subjects with Diabetes mellitus, Metabolic syndrome, Endocrine disorders, on statin drugs, not willing to participate. After informed consent, blood samples will be taken to quantify plasma levels of Leptin and Angiotensin II pre-operatively by ELISA. DNA will also be extracted from blood and SNPs will be analysed. The selected SNPs will be amplified by PCR and product will be purified and analysed by agarose gel electrophoresis. Patients will undergo liposuction and RNA will be isolated from subcutaneous adipose tissue for reverse transcription. After 3 months, patients will be called back for second session of liposuction and plasma level of Leptin and Angiotensin II will be quantified again. Similarly, expression profile of transcription factors will also be analysed again. Paired t-test will be used to compare clinical parameters like serum adipokines levels and adipokines expression levels and p value \<0.05 will be taken as statistically significant. The results will be utilized to determine impact of surgical reduction on plasma level and expression of the adipokines in minimizing cardiovascular risk factors.

Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity

This study investigates whether temporarily blocking the ghrelin receptor affects appetite and food intake in people with overweight or obesity. Ghrelin is a hormone that stimulates hunger; the researchers are using LEAP2, a naturally occurring hormone that blocks ghrelin's receptor, as a research tool to study what happens when ghrelin signaling is turned off for 24 hours. The study is a randomized, double-blind, placebo-controlled crossover trial. Eighteen adults with overweight or obesity (BMI ≥25 kg/m², elevated body fat percentage) will each complete two 24-hour study visits, at least 7 days apart: one with a continuous LEAP2 infusion and one with a saline placebo infusion, in random order. Neither participants nor most study staff will know which treatment is given on which visit. During each 24-hour visit, participants will receive a standardized liquid test meal followed by ad libitum (eat-until-comfortably-full) lunch, dinner, and breakfast meals, plus access to snacks. The main question the study aims to answer is whether LEAP2 reduces the total amount of food eaten over 24 hours compared to placebo. Additional measurements include blood glucose levels, subjective feelings of hunger and fullness (via questionnaires), stomach emptying rate, blood pressure and heart rate, and hormone levels (including growth hormone, FSH, and LH). Some participants will also undergo a small fat tissue biopsy to study how genes and proteins related to metabolism respond. The results are expected to improve understanding of how ghrelin and LEAP2 regulate appetite and metabolism in people with obesity, which may inform future approaches to treating obesity and related metabolic conditions.

Motivational Interviewing Intervention for Families With Overweight and Obesity

The COVID-19 lockdown fostered unhealthy eating habits and reduced physical activity levels, leading to weight gain, sedentary behavior, and increased anxiety and sleep disorders. Consequently, this study aims to evaluate the efficacy of an intervention using motivational interviewing to promote healthy diet and physical activity, improve body weight, reduce anxiety and depression, and enhance sleep quality and overall quality of life among families in Baja California and Sonora, Mexico, following the COVID-19 lockdown. This randomized controlled trial will include 60 individuals and their families in an intervention group receiving the motivational interviewing approach, and another 60 individuals and their families in a comparison group receiving traditional nutritional counseling; both groups will receive the same information but through different strategies. The intervention will be conducted using the motivational interviewing approach, delivered by professionals trained in this strategy. During each session, families will receive information regarding a nutritional plan and healthy physical activity. The project will involve physicians, nutritionists, and psychologists, as well as interns from medical and nutrition academic programs. Following the information sessions-which will take place in person within the comfort of each family's home-participants will be asked if they wish to set individual or family goals to be achieved over the subsequent 15-day periods during the first five months, or 30-day periods during the final five months. The information shared with participants will be based on practical guidelines for chronic disease prevention issued by the Ministry of Health. Topics will include the importance of consuming fruits, vegetables, and fiber-rich foods; strategies to reduce the intake of high-fat foods and sugary beverages; and the physical and emotional health benefits of physical activity. At the start of the study, anthropometric measurements will be taken, and assessments will be conducted regarding diet, physical activity levels, anxiety, depression, sleep quality, and quality of life; upon completion of the 10-month intervention, all assessment tools will be administered again to evaluate potential differences in the variables of interest. It is expected that, by the end of the intervention, participants will be able to modify their dietary and physical activity habits to achieve and maintain a healthy body weight, and that the strategies employed over the 10 months will enable them to develop a long-term healthy lifestyle, helping to prevent physical and mental illnesses among the children, adolescents, and adults in each family.

Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity

The purpose of this study is to evaluate body composition across a variety of medical, professional, and commercial devices, including: bioelectrical impedance analysis (BIA) devices, 3-dimensional optical imaging (3DO), manual anthropometry measurements, dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), and blood tests. The secondary study purpose is to compare body composition measurements from BIA devices, 3DO, and manual anthropometry measurements within a 1-week period for a subset of the study population. The study plans to enroll 300 healthy (having no life-threatening conditions or diseases; male and female) participants, 18 years of age or older.

Changes in Intestinal Permeability and Systemic Inflammation Following Fast Food Overfeeding.

The purpose of this study is to investigate whether lifestyle factors can alter gut barrier integrity and whether disruptions of the gut barrier can trigger systemic and tissue-specific inflammation. Twenty participants will undergo 14 days of fast-food overfeeding. Gut barrier function will be assessed before and after the intervention, alongside a wide palette of imaging techniques and biological analyses to characterize inflammatory status.

Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.

Purpose. This study will test whether daily Urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive the same structured lifestyle program (nutrition and sleep guidance); half will receive Urolithin A and half a matching placebo. Background. Weight loss can improve health but may also reduce skeletal muscle, especially in people with obesity. Aging and obesity are both linked to mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and low-grade inflammation. Urolithin A is a gut-derived, diet-related compound that promotes mitophagy and may support muscle function and metabolic health. Design. Single-center, randomized, placebo-controlled, parallel-group trial. About 100 adults aged 30-60 years with BMI \>30 kg/m² and elevated visceral adiposity will be enrolled and randomized in a 1:1 ratio (stratified by sex and age ≤45 vs ≥45 years). Blinding will include participants, study staff, and assessors. Intervention. Urolithin A 500 mg orally once daily vs matching placebo, for 24 weeks. A standardized lifestyle program for all participants: individualized energy restriction with higher protein intake, reduced carbohydrates, and time-restricted eating (11-hour eating window / 13-hour overnight fast); plus structured sleep-hygiene recommendations and light daily activity guidance. No other dietary supplements are allowed during the study. Main assessments. At baseline and regularly during the study, participants will undergo: Body composition by bioimpedance (InBody), including skeletal muscle and visceral fat indices. Muscle function (handgrip dynamometry; 30-second chair-stand). Cardiometabolic and inflammatory biomarkers from blood (standard biochemistry, lipids, glucose/HbA1c, CRP; exploratory cytokines/adipokines). Mitochondrial/aging biomarkers, including DNA-based epigenetic aging measures. Cardiovascular/ANS function (heart-rate variability and vascular indices; MaxPulse Medicore). Questionnaires on sleep quality, physical activity, and weight-management self-efficacy. Visits and duration. 6-month participation with baseline, 3-weekly check-ins, and a final visit for repeat testing and blood sampling. Outcomes. The study focuses on safety and on whether Urolithin A, compared with placebo, helps preserve functional muscle mass and improves mitochondrial, inflammatory, and metabolic biomarkers during weight loss. Who can join. Adults 30-60 years with obesity and higher visceral fat who are willing to follow the lifestyle program. Key medical exclusions (e.g., diabetes, active autoimmune disease, pregnancy) and supplement restrictions apply; full criteria are provided in the Eligibility section. Potential benefits and risks. Participants may benefit from weight loss support and close monitoring. Risks include blood draw discomfort and potential, usually mild, supplement-related side effects. Safety will be monitored throughout. Location and sponsor. The study is conducted at Charles University, Faculty of Medicine in Hradec Králové (Czech Republic) under the Department of Preventive Medicine.

Real-world Exploration of Digital iNnovation in the Management of Excess Weight

This is a real-world study. The purpose of this research is to explore whether a new National Institute for Health and Care Excellence (NICE)-approved digital weight-management model of care can improve health service delivery and address the Quintuple Aim of Healthcare (health outcomes, cost, patient and clinician experience, and health inequalities), for individuals living with obesity accessing National Health Service (NHS) Tier 3 weight-management services.

Project GAME ON! A Digital Comic Tool to Promote Healthy Behaviors

This clinical trial aims to evaluate an interactive, culturally relevant digital health promotion comic designed to support healthy dietary and physical activity behaviors among Black/African American and Latino children ages 8 to 12 years. The comic allows children's choices to affect the storyline and health content, with the goal of increasing engagement, empowering children, and improving attitudes, beliefs, and self-efficacy related to healthy behaviors. Caregivers will also receive newsletters reinforcing healthy dietary and physical activity behaviors at home. The main questions it aims to answer are: 1. Does an interactive, customizable "choose-your-own-adventure" style comic lead to greater engagement and acceptability compared to standard digital comic formats? 2. Is greater engagement with the comic associated with improved self-efficacy related to dietary and physical activity behaviors? Researchers will compare three study groups to evaluate differences in engagement, acceptability, and self-efficacy outcomes related to dietary and physical activity behaviors. Participants will: * Use a 6-week digital comic and health promotion website remotely * Complete surveys about engagement, attitudes, beliefs, and self-efficacy related to healthy behaviors * Receive periodic reminders and support messages during the intervention period * For caregivers in the enhanced and non-enhanced comic groups: receive newsletters promoting healthy dietary and physical activity behaviors at home

A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.

The goal of this clinical trial is to learn which dose of study drug IBIO-610 has the right balance of safety, tolerability and impact on body composition in participants with obesity.

The Impact of Continuous Glucose Monitoring on Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity

This randomized, crossover interventional study evaluates the effects of real-time (open) versus blinded continuous glucose monitoring (CGM) on glycemic variability, lifestyle behaviors, and metabolic outcomes in adults with prediabetes and overweight or obesity (BMI ≥ 27 kg/m²). Thirty participants will undergo both open and blinded CGM phases, separated by a washout period. The study aims to assess whether access to real-time glucose data promotes behavioral change and improves metabolic health compared with blinded CGM use.

Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity

Glucagon-like peptide (GLP1) drugs have quickly become a standard treatment for the adults with obesity. These drugs target the appetite control center of the brain, which clows the rate of stomach emptying, and makes a person feel full. The researchers are exploring this response in children. This study is being conducted to better understand how two food carbohydrates affect the appetite control center of the brain. The investigators want to see if a special carbohydrate powder that is mixed with 1 cup of water twice a day will appetite.

Study of Grape Consumption in Adaptation to Seasonal Photoperiod

The goal of this randomized clinical trial is to learn whether consuming grapes during their natural season can help the body adapt to the shorter daylight hours of winter. The study includes men and women aged 30-70 years with either normal weight or overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The main questions it aims to answer are: * Does seasonal grape consumption change circulating microRNAs, small molecules involved in regulating gene activity? * Does grape consumption influence sleep, physical activity, metabolic markers, body composition, muscle function, and gut bacteria during the transition to winter? Within each population group, researchers will compare participants consuming yogurt with freeze-dried grape powder with participants consuming the same yogurt without grape powder. Both groups will receive the same Mediterranean-style dietary guidance. Participants will: * Consume two yogurts daily for 3 weeks, either with or without a total daily dose of 16 grams of freeze-dried grape powder, equivalent to approximately 80 grams of fresh grapes. * Complete a further 2 weeks of follow-up without the grape intervention. * Attend an initial information visit and three assessment visits for blood sampling, stool sample collection, and measurements of body composition and muscle function. * Wear a wrist device to monitor sleep and physical activity. * Complete questionnaires, dietary records, and a sleep diary.

Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks

This is a nationwide, multi-center, long-term follow-up study of overweight and obese adults in China. The study aims to recruit approximately 26,000 participants across 39 hospitals to better understand how body weight affects the development of obesity-related diseases over a 3-year period. Eligible participants are adults aged 18 to 79 years with a body mass index (BMI) of 23 kg/m² or higher. Participants will be grouped into four categories based on their BMI: overweight, mild obesity, moderate obesity, and severe obesity. At the beginning of the study, all participants will undergo a comprehensive health assessment, including physical measurements, body composition analysis, blood tests, and lifestyle questionnaires. Participants will then be followed for 3 years with annual check-ins to track any new health conditions. The main goal is to identify the 3-year risk of developing conditions such as type 2 diabetes, fatty liver disease, high blood pressure, and heart disease in different weight groups. This information will help doctors better predict and prevent obesity-related health problems in the future. Participation is voluntary, and all personal information will be kept confidential.